FDA Wants Your Pain Points: New Guide for Patient-Centric Drug Tools
Published Date: 11/18/2025
Notice
Summary
The FDA just released new guidance to help drug makers and researchers better include patient experiences when creating or updating tools that measure how well treatments work. This means patients, caregivers, and industry folks can share real-world info to make drug development more patient-friendly. The guidance is effective now and aims to speed up smarter, more meaningful medical product decisions without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Patients Can Submit Experience Data
You (patients, caregivers, researchers, and medical product developers) can collect and submit patient experience and caregiver information to the FDA to be used for medical product development and regulatory decision-making. The final guidance, announced November 18, 2025, explains how to select, develop, or modify clinical outcome assessments that measure outcomes important to patients.
Guidance Adds No New Paperwork
The guidance contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved OMB collections, including control numbers such as 0910-0078, 0910-0332, 0910-0231, 0910-0120, 0910-0844, 0910-0756, 0910-0449, 0910-0001, 0910-0338, 0910-0014, 0910-0130, 0910-0303, and 0910-0429. That means the guidance itself does not create new reporting requirements for regulated parties.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16715, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16714, Agency Information Collection Activities; Proposed Collection; Comment Request; Third Party Disclosure and Recordkeeping Requirements for Reportable Food
The Food and Drug Administration (FDA or the Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of FDA's third-party disclosure and recordkeeping requirements for reportable food.
Previous / Next Documents
Previous: 2025-20152, Notice of OFAC Sanctions Actions
The U.S. Treasury’s OFAC just blocked the property of two people from Colombia linked to illegal drug activities. From October 24, 2025, Americans can’t do business with them, freezing their assets under U.S. law. This move aims to cut off money and resources fueling the global drug trade.
Next: 2025-20155, Lightweight Thermal Paper From the People's Republic of China: Final Results of the Expedited Third Sunset Review of the Countervailing Duty Order
The U.S. Department of Commerce decided to keep extra taxes on lightweight thermal paper imported from China because stopping them could let unfair government help continue. This affects Chinese exporters and U.S. companies like Domtar that make similar paper here. These duties stay in place starting November 18, 2025, helping protect American businesses from unfair competition.